Physician profile
Anne Stefani
NPI 1588660039
$1,128.88
in general payments reported to CMS, 2019-2025
20 companies · $351 in 2025
The $351 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $52.31 · 2020: $62.07 · 2021: $109 · 2022: $176 · 2023: $249 · 2024: $130 · 2025: $351.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $730.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $729.72 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Radius Health, INC. | $194.62 | 2019-2025 | Tymlos |
| Pfizer INC. | $128.23 | 2022-2025 | |
| Novo Nordisk INC | $115.05 | 2024-2025 | Wegovy |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $77.90 | 2022-2025 | Xifaxan |
| Abbvie INC. | $76.91 | 2021-2025 | Qulipta |
| Astrazeneca Pharmaceuticals LP | $73.07 | 2021-2025 | Airsupra, Breztri |
| Idorsia Pharmaceuticals US INC | $56.48 | 2023 | Quviviq |
| Eisai INC. | $47.69 | 2020-2021 | |
| Bausch Health US, LLC | $46.62 | 2019-2020 | |
| Astellas Pharma US INC | $43.47 | 2024-2025 | Veozah |
| Amgen INC. | $41.89 | 2022 | |
| Vertex Pharmaceuticals Incorporated | $40.15 | 2025 | |
| Glaxosmithkline, LLC. | $36.09 | 2022-2023 | Arexvy, Shingrix |
| Lilly USA, LLC | $28.01 | 2021 | |
| Esperion Therapeutics, INC. | $27.00 | 2023-2025 | Nexletol |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dexcom, INC. | $22.23 | 2024 | Dexcom G6 Transmitter |
| Ibsa Pharma INC. | $20.95 | 2023 | Tirosint, Licart |
| Sanofi Pasteur INC. | $19.85 | 2025 | |
| Supernus Pharmaceuticals, INC. | $19.17 | 2023 | Qelbree |
| Romark Laboratories, Lc | $13.50 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anne Stefani listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.